Connect with us

Industry

First medical cannabis flower available for patients in France

The first prescriptions of flower are set to be available for patients on the French medical cannabis trial

Published

on

The products are set to be available for patients in the coming weeks

The first prescriptions of medical cannabis flower are set to be available for patients on the French medical cannabis pilot programme, in the coming weeks.

The first batches of dried medical cannabis flower, provided by Aurora and distributed by Ethypharm, are now available to the healthcare professionals on the first-ever French pilot programme.

The two firms were selected by the National Agency for the Safety of Medicines and Health Products (ANSM) as sole primary suppliers in the categories of medical cannabis dried flowers, following the launch of the trial earlier this year. 

Up to 3,000 patients will benefit from the two-year trial led by ANSM.

The first batches of the three types of pharmaceutical quality pharmaceutical-grade medical cannabis dried flowers (THC dominant, balanced and CBD dominant) – developed by the Aurora Nordic, production facility in Odense, Denmark – were delivered a few weeks ago to the French authorities. 

Aurora supplies first medical cannabis flower to French pilot

Aurora Nordic, the company’s largest greenhouse production facility on European soil. Credit: Aurora Cannabis

Ethypharm and Aurora Europe were amongst the six producer-and-distributor tandems selected to provide medical cannabis products.

They were nominated as the primary supplier for all the three lots they applied for, which are: Aurora 20/1 XPE (high-THC dried flowers), Aurora 8/8 XPE (THC: CBD balanced dried flowers) and Aurora 1/12 XPE (high-CBD dried flowers).

Dried flowers are to be administrated with a vaporiser by STORZ & BICKEL, a well-known product tested and used by patients across Europe, recently selected by the ANSM. 

This solution was particularly expected to complement the other medical cannabis forms already made available in the pilot.

Dr Axel Gille, president of Aurora Europe, commented: “Aurora’s participation in the French pilot program is a significant step toward providing better access to patients and will support the destigmatisation of medical cannabis in France.”

He added: “Aurora has a proven track record of supporting the advancement of international medical cannabis markets alongside government bodies and with a deep commitment to compliance and excellence in the large-scale production of high-quality pharmaceutical grade medical cannabis. If successful, this pilot programme could lead to one of the largest regulated markets for medical cannabis in Europe.”

 

Sarah Sinclair is a respected cannabis journalist writing on subjects related to science, medicine, research, health and wellness. She is managing editor of Cannabis Health, the UK’s leading title covering medical cannabis and CBD, and sister titles, Cannabis Wealth and Psychedelic Health. Sarah has an NCTJ journalism qualification and an MA in Journalism from the University of Sunderland. Sarah has over six years experience working on newspapers, magazines and digital-first titles, the last two of which have been in the cannabis sector. She has also completed training through the Medical Cannabis Clinicians Society securing a certificate in Medical Cannabis Explained. She is a member of PLEA’s (Patient-Led Engagement for Access) advisory board, has hosted several webinars on cannabis and women's health and has moderated at industry events such as Cannabis Europa. Sarah Sinclair is the editor of Cannabis Health. Got a story? Email sarah@handwmedia.co.uk / Follow us on Twitter: @CannabisHNews / Instagram: @cannabishealthmag

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2023 PP Intelligence Ltd.